Summary of a letter written to Healthcare Professionals regarding Omniscan
In a letter dated December 22, 2006 Larry Bell, MD, Vice President, Global Head of Regulatory and Pharmacovigilance at GE Healthcare wrote a letter to healthcare professionals stating the latest information regarding OmniscanT contrasting agent used in MRIs and MRAs. In it, Bell informs the healthcare professional establishment of new case reports strengthening the association between OmniscanT (gadodiamide) injections and the development of the serious medical condition known as Nephrogenic Systemic Fibrosis (NSF) a.k.a. Nephrogenic Fibrosing Dermopathy (NFD). Since June 2006, when GE Healthcare issued the safety advisory regarding OmniscanT and NSF, they have received additional reports of over 50 cases.
Continue reading "Summary of a letter written to Healthcare Professionals regarding Omniscan" »
